Rising geopolitical instability is reshaping Serbia’s economic risk profile, revealing a significant vulnerability in the country’s heavy reliance on imported pharmaceuticals. This sector has emerged as the second-largest component of Serbia’s imports, following oil, with a trade deficit exceeding €1.16 billion. Despite its importance, the issue has received limited public attention, even as global tensions, particularly in the Middle East, raise concerns about supply chain disruptions.
The structural nature of this dependency is evident in Serbia’s import-export dynamics. The country imports pharmaceuticals, medical devices, and raw materials at levels that far surpass domestic production capabilities. Annual imports exceed €1.9 billion, while exports are only about €739.6 million, resulting in a persistent and widening trade deficit.
Over the past two decades, the transformation of Serbia’s pharmaceutical industry has played a crucial role in this dependency. Once dominated by large domestic producers like Galenika and Jugoremedija, the sector has largely been privatized or diminished, with ownership shifting towards multinational corporations. This shift has reduced Serbia’s strategic autonomy in a sector critical for public health and profitability.
Currently, Serbia has 24 companies involved in pharmaceutical production; however, only seven facilities engage in full manufacturing processes. Many others are limited to packaging or partial processing. This fragmented production landscape means that even domestically manufactured medicines often rely heavily on imported active pharmaceutical ingredients.
The global structure of pharmaceutical supply chains exacerbates this vulnerability. Key chemical compounds and active ingredients are predominantly produced in large-scale hubs located in China, India, and South Korea. This concentration creates an upstream dependency that affects not only Serbia but also major Western markets.
Geopolitical shocks can disrupt supply chains indirectly through energy and logistics channels. Conflicts impacting oil supply routes or transport corridors can hinder the movement of raw materials and finished products, leading to widespread disruptions across global supply chains.
For Serbia, this linkage is particularly pronounced. Although pharmaceuticals are not directly linked to energy markets, the logistics infrastructure supporting these supplies—such as shipping routes and air freight capacity—is sensitive to geopolitical tensions. Any disruption could lead to delayed deliveries or increased costs.
Industry experts indicate that while immediate risks are manageable—thanks to inventory buffers maintained by pharmaceutical companies—long-term stability is less assured. Many raw materials are transported by air rather than sea, which mitigates some risks associated with maritime disruptions. Additionally, key supply regions are geographically distant from current conflict zones.
However, Serbia’s reliance on imports from Hungary, Switzerland, Germany, Slovenia, and France highlights a geographically concentrated dependency that complicates its position within the European pharmaceutical ecosystem. In contrast to its broad export markets, this asymmetry reinforces Serbia’s status as a net importer.
The domestic market reflects this imbalance starkly; out of over 56,000 registered medical products available in Serbia, approximately 1,300 are produced locally. Even in areas where Serbia demonstrates relative strength—like dietary supplements—the balance between imports and exports remains nearly equal in value.
The convergence of these factors indicates systemic exposure rather than merely a temporary imbalance. In prolonged geopolitical crises, Serbia could face compounded risks such as increased import costs due to rising energy prices and logistical bottlenecks affecting delivery times.
This evolving situation shifts policy discussions from efficiency toward resilience in the pharmaceutical sector. Achieving full self-sufficiency may not be economically viable for a smaller market; however, restoring certain segments—particularly in generic drug production—could become essential for national security.
As discussions around economic vulnerability broaden to include pharmaceutical security alongside energy security, Serbia finds itself at a critical intersection where both sectors significantly impact its stability during periods of geopolitical stress.
